Pharmacological treatment of nephropathic cystinosis with cysteamine

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2255-2262

  Kleta, Robert ^a,b,c   Gahl, William A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Intramural Program   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

CTNS; Cystamine; Cysteamine; Cystinosin; Lysosomal storage disorder; Nephropathic cystinosis; Renal Fanconi syndrome

Indexed keywords

AMINO ACID TRANSPORTER; ASCORBIC ACID; CREATININE; CYSTAFOS; CYSTEAMINE DERIVATIVE; CYSTINE; FW 77; IND 40593; LEVOTHYROXINE; MERCAPTAMINE; MERCAPTAMINE TARTRATE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; CHILD; CLINICAL TRIAL; CREATININE CLEARANCE; CYSTINOSIS; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DECOMPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; FANCONI RENOTUBULAR SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC CODE; GLOMERULUS FILTRATION RATE; HALITOSIS; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY METABOLISM; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYSOSOME MEMBRANE; NAUSEA; NONHUMAN; REVIEW; SEIZURE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TERATOGENICITY; THYROID FUNCTION; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYSTEAMINE; CYSTINOSIS; FANCONI SYNDROME; HUMANS; INFANT;

EID: 8544282463     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2255     Document Type: Review

References (64)

1. GAHL WA, BASHAN N, TIETZE F, BERNARDINI I, SCHULMAN JD: Lysosomal cystine transport is defective in cystinosis. Science (1982) 217(4566):1263-1265.
2. TOWN M, JEAN G, CHERQUI S et al.: A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat. Genet. (1998) 18(4):319-324.
3. GAHL WA, THOENE J, SCHNEIDER JA: Cystinosis: a disorder of lysosomal membrane transport. In: The Metabolic & Molecular Bases of Inherited Disease (Volume III). Scriver CR, Beaudet AL, Valle D, Sly WS (Eds), 8th edn, McGraw-Hill, New York, USA (2001):5085-5108.
4. GAHL WA, THOENE JG, SCHNEIDER JA: Cystinosis. N. Engl. J. Med. (2002) 347(2):111-121.
5. THE CYSTINOSIS COLLABORATIVE RESEARCH GROUP: Linkage of the gene for cystinosis to markers on the short arm of chromosome 17. Nat. Genet. (1995) 10(2):246-248.
6. SHOTELERSUK V, LARSON D, ANIKSTER Y et al.: CTNS mutations in an American-based population of cystinosis patients. Am. J. Hum. Genet. (1998) 63(5):1352-1362.
7. ANIKSTER Y, LUCERO C, TOUCHMAN JW et al.: Identification and detection of the common 65-kb deletion breakpoint in the nephropathic cystinosis gene (CTNS). Mol. Genet. Metab. (1999) 66(2):111-116.
8. FORESTIER L, JEAN G, ATTARD M et al.: Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay. Am. J. Hum. Genet. (1999) 65(2):353-359.
9. TOUCHMAN JW, ANIKSTER Y, DIETRICH NL et al.: The genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome Res. (2000) 10(2):165-173.
10. ANIKSTER Y, LUCERO C, GUO J et al.: Ocular nonnephropathic cystinosis: clinical, biochemical, and molecular correlations. Pediatr. Res. (2000) 47(1):17-23.
11. GRETZ N, MANZ F, AUGUSTIN R et al.: Survival time in cystinosis. A collaborative study. Proc. Eur. Dial. Transplant. Assoc. (1983) 19:582-589.
12. THEODOROPOULOS DS, KRASNEWICH D, KAISERKUPFER MI, GAHL WA: Classical nephropathic cystinosis as an adult disease. JAMA (1993) 270(18):2200-2204.
13. GAHL WA, DALAKAS MC, CHARNAS L et al.: Myopathy and cystine storage in muscles in a patient with nephropathic cystinosis. N. Engl. J. Med. (1988) 319(22):1461-1464.
14. CHARNAS LR, LUCIANO CA, DALAKAS M et al.: Distal vacuolar myopathy in nephropathic cystinosis. Ann. Neurol. (1994) 35(2):181-188.
15. SONIES BC, EKMAN EF, ANDERSSON HC et al.: Swallowing dysfunction in nephropathic cystinosis. N. Engl. J. Med. (1990) 323(9):565-570.
16. KAISER-KUPFER MI, CARUSO RC, MINKLER DS, GAHL WA: Long-term ocular manifestations in nephropathic cystinosis. Arch. Ophthalmol. (1986) 104(5):706-711.
17. FIVUSH B, GREEN OC, PORTER CC, BALFE JW, O'REGAN S, GAHL WA: Pancreatic endocrine insufficiency in posttransplant cystinosis. Am. J. Dis. Child. (1987) 141(10):1087-1089.
18. FIVUSH B, FLICK JA, GAHL WA: Pancreatic exocrine insufficiency in a patient with nephropathic cystinosis. J. Pediatr. (1988) 112(1):49-51.
19. ANIKSTER Y, LACBAWAN F, BRANTLY M et al.: Pulmonary dysfunction in adults with nephropathic cystinosis. Chest (2001) 119(2):394-401.
20. CHIK CL, FRIEDMAN A, MERRIAM GR, GAHL WA. Pituitary-testicular function in nephropathic cystinosis. Ann. Intern. Med. (1993) 119(7 Pt 1):568-575.
21. EHRICH JH, STOEPPLER L, OFFNER G, BRODEHL J: Evidence for cerebral involvement in nephropathic cystinosis. Neuropadiatrie (1979) 10(2):128-137.
22. FINK JK, BROUWERS P, BARTON N et al.: Neurologic complications in long-standing nephropathic cystinosis. Arch. Neurol. (1989) 46(5):543-548.
23. GAHL WA, TIETZE F, BUTLER JD, SCHULMAN JD: Cysteamine depletes cystinotic leucocyte granular fractions of cystine by the mechanism of disulphide interchange. Biochem. J. (1985) 228 3):545-550.
24. PISONI RL, THOENE JG, CHRISTENSEN HN: Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. J. Biol. Chem. (1985) 260(8):4791-4798.
25. THOENE JG, OSHIMA RG, CRAWHALL JC, OLSON DL, SCHNEIDER JA: Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J. Clin. Invest. (1976) 58(1):180-189.
26. GAHL WA, REED GF, THOENE JG et al.: Cysteamine therapy for children with nephropathic cystinosis. N. Engl. J. Med. (1987) 316(16):971-977.
27. MARKELLO TC, BERNARDINI IM, GAHL WA: Improved renal function in children with cystinosis treated with cysteamine. N. Engl. J. Med. (1993) 328(16):1157-1162.
28. KIMONIS VE, TROENDLE J, YANG ML et al.: Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J. Clin. Endocrinol. Metab. (1995) 80 11):3257-3261.
29. KAISER-KUPFER MI, FUJIKAWA L, KUWABARA T, GAHL WA: Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N. Engl. J. Med. (1987) 316(13):775-779.
30. KAISER-KUPFER MI, GAZZO MA, DATILES MB et al.: A randomized placebo-controlled trial of cysteamine eyedrops in nephropathic cystinosis. Arch. Ophthalmol. (1990) 108 5):689-693.
31. GAHL WA, KUEHL EM, IWATA F, LINDBLAD A, KAISER-KUPFER MI: Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol. Genet. Metab. (2000) 71 1-2):100-120.
32. GAHL WA: Early oral cysteamine therapy for nephropathic cystinosis. Eur. J. Pediatr. (2003) 162(Suppl. 1):S38-S41.
33. KLETA R, BERNARDINI I, UEDA M et al.: Long-term follow-up of well-treated nephropathic cystinosis patients. (2004) J. Pediatr. (In Press).
34. SMOLIN LA, CLARK KF, SCHNEIDER JA: An improved method for heterozygote detection of cystinosis, using polymorphonuclear leukocytes. Am. J. Hum. Genet. (1987) 41(2):266-275.
35. SMITH ML, PELLETT OL, CASS MM et al.: Prenatal diagnosis of cystinosis utilizing chorionic villus sampling. Prenat. Diagn. (1987) 7(1):23-26.
36. BENDAVID C, KLETA R, LONG R et al.: FISH diagnosis of the common 57-kb deletion in CTNS causing cystinosis. Human Genet. (2004) (In Press).
37. CHERQUI S, SEVIN C, HAMARD G et al.: Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol. Cell. Biol. (2002) 22(21):7622-7632.
38. PARK M, HELIP-WOOLEY A, THOENE J: Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J. Am. Soc. Nephrol. (2002) 13 12):2878-2887.
39. YUDKOFF M, FOREMAN JW, SEGAL S: Effects of cysteamine therapy in nephropathic cystinosis. N. Engl. J. Med. (1981) 304 3):141-145.
40. GAHL WA, THOENE JG, SCHNEIDER JA et al.: NIH conference. Cystinosis: progress in a prototypic disease. Ann. Intern. Med. (1988) 109(7):557-569.
41. GAHL WA, CHARNAS L, MARKELLO TC et al.: Parenchymal organ cystine depletion with long-term cysteamine therapy. Biochem. Med. Metab. Biol. (1992) 48(3):275-285.
42. DA SILVA VA, ZURBRUGG RP, LAVANCHY P et al.: Long-term treatment of infantile nephropathic cystinosis with cysteamine. N. Engl. J. Med. (1985) 313(23):1460-1463.
43. VANT HOFF WG, GRETZ N: The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire. Pediatr. Nephrol. (1995) 9(6):685-689.
44. NIAUDET P, TETE MJ, BROYER M: Renal disease in cystinosis. In: Cystinosis. Broyer M (Ed.), Elsevier, Paris, France (1999):36-41.
45. PROESMANS W, BATEN E, HOOGMARTENS J, BRUYNEEL P: Nephropathic cystinosis: effect of long-term cysteamine therapy. Clin. Nephrol. (1987) 27(6):309-312.
46. SCHNEIDER JA: Treatment of cystinosis: Simple in principle, difficult in practice. (2004) J. Pediatr. (In Press).
47. Cysteamine for cystinosis. Med. Lett. Drugs Ther. (1994) 36(938):118.
48. SCHNEIDER JA. Approval of cysteamine for patients with cystinosis. Pediatr. Nephrol. (1995) 9(2):254.
49. KLETA R, GAHL WA: Cystinosis: antibodies and healthy bodies. J. Am. Son Nephrol. (2002) 13(8):2189-2191.
50. SKOVBY F, KLETA R, ANIKSTER Y, CHRISTENSEN R, GAHL WA. Cystinosis in Denmark: Mutation analysis and treatment with cystamine, the disulfide of cysteamine. Am. J. Hum. Genet. (2002) 71 4):S413 (Abstract).
51. IWATA F, KUEHL EM, REED GF et al.: A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis. Mol. Genet. Metab. (1998) 64(4):237-242.
52. TSILOU ET, THOMPSON D, LINDBLAD AS et al.: A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br. J. Ophthalmol. (2003) 87(1):28-31.
53. TENNEZE L, DAURAT V, TIBI A, CHAUMET-RIFFAUD P, FUNCKBRENTANO C: A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Br. J. Clin. Pharmacol. (1999) 47(1):49-52.
54. BELLDINA EB, HUANG MY, SCHNEIDER JA, BRUNDAGE RC, TRACY TS: Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br. J. Clin. Pharmacol. (2003) 56(5):520-525.
55. WENNER WJ, MURPHY JL: The effects of cysteamine on the upper gastrointestinal tract of children with cystinosis. Pediatr. Nephrol. (1997) 11(5):600-603.
56. DOHIL R, NEWBURY RO, SELLERS ZM, DEUTSCH R, SCHNEIDER JA: The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J. Pediatr. (2003) 143 2)224-230.
57. CORDEN BJ, SCHULMAN JD, SCHNEIDER JA, THOENE JG: Adverse reactions to oral cysteamine use in nephropathic cystinosis. Dev. Pharmacol. Ther. (1981) 3(1):25-30.
58. BECKMAN DA, MULLIN JJ, ASSADI FK: Developmental toxicity of cysteamine in the rat: effects on embryo-fetal development. Teratology (1998) 58(3-4):96-102.
59. SOOHOO N, SCHNEIDER JA, KAPLAN RM: A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis. Med. Decis. Making (1997) 17(2):193-198.
60. MEWISSEN DJ, BRUCER M: Late effects of gamma radiation on mice protected with cysteamine or cystamine. Nature (1957) 179 4552):201-202.
61. RAY-CHAUDHURI SP, CHAUDHURI JP, CHATTERJEE S: Cysteamine protection of grasshopper chromosomes from X-ray-induced aberrations under aerobic and anaerobic conditions. Int. J. Radiat. Biol. (1962) 5(6):591-595.
62. OSHIMA RG, WILLIS RC, FURLONG CE, SCHNEIDER JA: Binding assays for amino acids. The utilization of a cystine binding protein from Escherichia coli for the determination of acid-soluble cystine in small physiological samples. J. Biol. Chem. (1974) 249 19):6033-6039.
63. KLETA R, ANIKSTER Y, LUCERO C et al.: CTNS mutations in African American patients with cystinosis. Mol. Genet. Metab . (2001) 74(3):332-337.
64. WINBERG J: The 24-hour true endogenous creatinine clearance in infants and children without renal disease. Acta Paediatr. (1959) 48:443-452.